Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on the back of its HIV portfolio and new drug launches.
Trump nominates vocal Fed critic Miran as interim governor, signaling potential shift in monetary policy.
Australian software firm Iress in early-stage takeover talks with Blackstone and Thoma Bravo, amid broader surge of private equity activity targeting Australia-listed software companies.
Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on the back of its HIV portfolio and new drug launches.
Trump nominates vocal Fed critic Miran as interim governor, signaling potential shift in monetary policy.
Australian software firm Iress in early-stage takeover talks with Blackstone and Thoma Bravo, amid broader surge of private equity activity targeting Australia-listed software companies.
